Browse > Article
http://dx.doi.org/10.3345/kjp.2008.51.1.67

Clinical outcomes of hematopoietic stem cell transplantation from HLA-matched parental donor in childhood acute leukemia  

Cha, Eun Young (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Lee, Moon Hee (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Lee, Jae Wook (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Kwon, Young Joo (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Lee, Dae Hyoung (Department of Pediatrics, College of Medicine, Hallym University)
Park, Young-Shil (Department of Pediatrics, College of Medicine, Kyung Hee University)
Chung, Nak Gyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Jeong, Dae Chul (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Cho, Bin (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Kim, Hack Ki (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Publication Information
Clinical and Experimental Pediatrics / v.51, no.1, 2008 , pp. 67-72 More about this Journal
Abstract
Purpose : In this study, we retrospectively analyzed the clinical outcomes of patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) grafted from HLA-matched parents. Methods : Seven children with acute leukemia (4 acute lymphoblastic leukemia, 3 acute myeloid leukemia) in first complete remission received allogeneic HSCT from their respective parents at the St. Marys Hospital between April, 1999 and October, 2005. The median age of patients at transplantation was 5 years (range, 1-11 years; 2 male, 5 female) and the median age of donors was 35 years (range, 30-41 years; 5 male, 2 female). We investigated the clinical outcomes such as engraftment, acute and chronic graft-versus-host disease (GVHD), transplant-related morbidity and mortality, relapse and survival. Results : Median time from transplantation to last follow-up was 69.5 months (range, 18.8-96.5 months). All patients were successfully engrafted, with a median time of 11 days (range, 10-16 days) and 26 days (range, 13-39 days) for neutrophil and platelet recovery, respectively. Grade II acute GVHD occurred in 3, and grade III acute GVHD in 1 of 7 recipients. Extensive chronic GVHD developed in 2, and limited chronic GVHD in 1 of 7 recipients. Death from transplant-related complications occurred in 1, and relapse occurred in 1 of 7 recipients. Estimated 5-year overall survival was $83{\pm}15%$. Conclusion : The clinical outcomes of recipients who underwent HSCT from HLA-matched parents were comparable to those of patients who received HSCT grafted from HLA-matched sibling donors in childhood leukemia. HLA typing of parents, as well as siblings will increase the likelihood of finding an HLA-matched family donor for patients who need HSCT.
Keywords
Acute leukemia; Hematopoietic stem cell transplantation; HLA-matched parent;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997;15:1767-77   DOI
2 Kim HK, Cho B, Chung NG, Jeong DC, Jang PS, Kim SY, et al. Two hundred cases of allogeneic hematopoietic stem cell transplantation in children: single center study. Korean J Hemato Stem Cell Trans 2002;7:63-71
3 Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304   DOI   ScienceOn
4 Zecca M, Pession A, Messina C, Bonetti F, Favre C, Prete A, et al. Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings. J Clin Oncol 1999;17:1838-46   DOI
5 Meyers JD. Prevention and treatment of cytomegalovirus infection after marrow transplantation. Bone Marrow Transplant 1988;3:95-104
6 Henslee-Downey PJ, Parrish RS, MacDonald JS, Romond EH, Marciniak E, Coffey C, et al. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versushost disease following haploidentical marrow transplant. Transplantation 1996;61:738-45   DOI
7 Lee KW, Oh DH, Lee C, Yang SY. Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens 2005;65:437-47   DOI   ScienceOn
8 Hongeng S, Krance RA, Bowman LC, Srivastava DK, Cunningham JM, Horwitz EM, et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet 1997;350:767-71   DOI   ScienceOn
9 Marks DI, Khattry N, Cummins M, Goulden N, Green A, Harvey J, et al. Haploidentical stem cell transplantation for children with acute leukaemia. Br J Haematol 2006;134:196-201   DOI   ScienceOn
10 Eapen M, Rubinstein P, Zhang MJ, Camitta BM, Stevens C, Cairo MS, et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol 2006;24:145-51   DOI   ScienceOn
11 Petersdorf EW. Risk assessment in haematopoietic stem cell transplantation: histocompatibility. Best Pract Res Clin Haematol 2007;20:155-70   DOI   ScienceOn
12 Mehta J, Singhal S, Gee AP, Chiang KY, Godder K, Rhee Fv F, et al. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: singlecenter experience of 201 patients. Bone Marrow Transplant 2004;33:389-96   DOI   ScienceOn
13 Oudshoorn M, Lie JLWT, Bakker JNA, Van Der Zanden HGM, Claas FHJ. Finding the most suitable allogeneic he-matopoietic stem cell donor. In : Atkinson K, Champlin R, Ritz J, Fibbe WE, Ljungman P, Brenner ML, editors. Clinical Bone Marrow And Blood Stem Cell Transplantation. 3rd ed. Cambridge : Cambridge University Press, 2004:369-82
14 Greinix HT, Fae I, Schneider B, Rosenmayr A, Mitterschiffthaler A, Pelzmann B, et al. Impact of HLA class I highresolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplant 2005;35:57-62   DOI   ScienceOn
15 Alonzo TA, Wells RJ, Woods WG, Lange B, Gerbing RB, Buxton AB, et al. Postremission therapy for children with acute myeloid leukemia: the childrens cancer group experience in the transplant era. Leukemia 2005;19:965-70   DOI   ScienceOn
16 Klingebiel T, Handgretinger R, Lang P, Bader P, Niethammer D. Haploidentical transplantation for acute lymphoblastic leukemia in childhood. Blood Rev 2004;18:181-92   DOI   ScienceOn
17 Barrett AJ, Horowitz MM, Pollock BH, Zhang MJ, Bortin MM, Buchanan GR, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994;331:1253-8   DOI   ScienceOn
18 Uderzo C, Rondelli R, Dini G, Dallorso S, Messina C, Miniero R, et al. High-dose vincristine, fractionated total-body irradiation and cyclophosphamide as conditioning regimen in allogeneic and autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission: a 7-year Italian multicentre study. Br J Haematol 1995;89:790-7   DOI   ScienceOn
19 Kim HK, Cho B, Chung NG, Jeong DC, Kim SY, Lee HJ, et al. One hundred cases of HLA-matched sibling allogeneic bone marrow transplantation in children : Single center study. J Korean Pediatr Soc 1999;43:402-10
20 Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, et al. Analysis of risk factors for the development of GVHD after T celldepleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Biol Blood Marrow transplant 2001;7:620-30   DOI   ScienceOn
21 Mrtelli MF, Aversa F, Velardi A, Reisner Y. HLA-mismatched family member hematopoietic stem cell transplantation. In : Atkinson K, Champlin R, Ritz J, Fibbe WE, Ljungman P, Brenner ML, editors. Clinical Bone Marrow And Blood Stem Cell Transplantation. 3rd ed. Cambridge : Cambridge University Press, 2004:1011-26
22 Miller W, Flynn P, McCullough J, Balfour HH Jr, Goldman A, Haake R, et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-vhost disease. Blood 1986;67:1162-7
23 Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104:1923-30   DOI   ScienceOn
24 Chalandon Y, Tiercy JM, Schanz U, Gungor T, Seger R, Halter J, et al. Impact of high-resolution matching in allogeneic unrelated donor stem cell transplantation in Switzerland. Bone Marrow Transplant 2006;37:909-16   DOI   ScienceOn
25 Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001;97:56-62   DOI   ScienceOn
26 Cho EY, Park YS, Lee DH, Park JK, Choi SR, Kim SY, et al. CMV antigenemia following pediatric hematopoietic stem cell transplantation : risk factors and outcomes. Korean J Pediatr 2006;49:173-80   DOI